113 / 374
XXXIX
Congreso de la Sociedad Española de Inmunología Clínica y Alergología Pediátrica
113
count is a useful biomarker to identify
patients with severe eosinophilic asth-
ma. Ann AmThorac Soc 2014;11:531–6.
53. Fleming L,Wilson N, Regamey N, Bush
A. Use of sputum eosinophil counts to
guide management in children with
severe asthma.Thorax 2012;67:193–8.
54. Beck LA, Thaçi D, Hamilton JD, Gra-
ham NM, Bieber T, Rocklin R, et al.
Dupilumab treatment in adults with
moderate-to-severe atopic dermatitis.
N Engl J Med 2014;371:130–9.
55. Hamilton JD, Suárez-Fariñas M, Dhin-
gra N, Cardinale I, Li X, Kostic A, et al.
Dupilumab improves the molecular
signature in skin of patients with mode-
rate-to-severe atopic dermatitis. J Aller-
gy Clin Immunol 2014;134:1293–300.
56. Oldhoff JM, Darsow U, Werfel T, Kat-
zer K, Wulf A, Laifaoui J, et al. Anti-IL-5
recombinant humanized monoclo-
nal antibody (mepolizumab) for the
treatment of atopic dermatitis. Allergy
2005;60:693–6.
adults with asthma. N Engl J Med
2011;365:1088–98.
48. De Boever EH, Ashman C, Cahn AP,
Locantore NW, Overend P, Pouliquen
IJ, et al. Efficacy and safety of an anti-
IL-13 mAb in patients with severe asth-
ma: a randomized trial. J Allergy Clin
Immunol 2014;133:989–96.
49. Piper E, Brightling C, Niven R, Oh C,
Faggioni R, Poon K, et al. A phase II
placebo-controlled study of tralokinu-
mab in moderate-to-severe asthma.
Eur Respir J 2013;41:330–8.
50. Wenzel S, Ford L, Pearlman D, Spector
S, Sher L, Skobieranda F, et al. Dupilu-
mab in persistent asthma with eleva-
ted eosinophil levels. N Engl J Med
2013;368:2455–66.
51. Domingo C. Omalizumab for severe
asthma: Efficacy beyond the atopic pa-
tient? Drugs 2014;74:521–33.
52. Katz LE, Gleich GJ, Hartley BF, Yan-
cey SW, Ortega HG. Blood eosinophil